Mirimus
Brooklyn
About Mirimus
Mirimus produces custom genetically engineered mouse models (GEMMs) with reverse gene silencing capabilities by harnessing the power of RNA interference (RNAi). By fusing together proprietary RNAi technology with an efficient mouse engineering strategy, Mirimus holds the leading platform for rapid and cost-effective production of RNAi-GEMMs that serve as invaluable pre-clinical tools to help direct drug discovery research. RNAi-GEMMs are a unique and superior alternative to knockout mice that increase the confidence of drug discovery research prior to entering clinical trials. The ability to transiently suppress a specific gene target within the whole organism makes RNAi-GEMMs an effective tool to be used for target identification and/or validation as well as assessment of target efficacy and toxicity. Transgenic RNAi rodents will undoubtedly become indispensible to the pharmaceutical and biotechnology industry by directing the development of effective and well-tolerated therapeutic strategies to combat the leading ailments of humankind.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Private
- Employees: 11 – 50
- Estimated revenue: $1K – $10K
- Total funding: $2.5M
- Funding stage: Early Stage Venture
- Last round: Grant (Mar 2021)
- Website: mirimus.com
- Phone: +1 (833) 647-4687
Industries & Categories
Biotechnology, Genetics, Health Diagnostics, Life Science, Oncology
Social Profiles
Canonical: https://fsome.com/organization/mirimus-37114 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.